


# CBSA NEWS IN REVIEW



A BRIEF OVERVIEW OF COLORADO'S MEDICAL DEVICE AND BIOPHARMA INDUSTRIES

11 April – 17 April

## COMPANY SPOTLIGHT

- **Accera, Inc.** (Broomfield) announced the formation of Neuera Pharmaceuticals, Inc. Neuera will focus on the discovery of drugs for neurodegenerative diseases and other neurological conditions. Neuera will operate as a wholly owned subsidiary of Accera until completion of a \$12M Series A round, to which several existing Accera investors have committed, at which point it will form a stand-alone company. This move will separate the sales and marketing of Accera's recently launched medical food Axona for Alzheimer's Disease from the small molecule drug research and discovery efforts.
- **GlobelImmune, Inc** (Louisville) announced the initiation of a Phase I clinical trial of Tarmogen GI-6207 to investigate its safety and tolerability in patients with metastatic cancers that over-express carcinoembryonic antigen (CEA). The trial is an open-label dose escalating study with a primary endpoint of safety and tolerability and secondary endpoints including measures of the levels of CEA-specific T cells and evidence of clinical benefit.
- **CaridianBCT** (Lakewood) announced the introduction of a new three component (3C) protocol for the Atreus Whole Blood Processing System, the first single system for whole blood processing, in the European Market. The Altreus 3C protocol, which received a European CE Mark (regulatory approval) in 2008, separates units of whole blood into red blood cells, plasma, and platelets. The 3C platelet unit is an improvement to the previous generation Atreus 2C system, which automated many blood processing steps to produce red blood cell and plasma units.
- Two Colorado companies reported new data at the American Association for Cancer Research Meeting currently taking place in Denver:
  - **Allos Therapeutics, Inc** (Westminster) reported new data demonstrating the anticancer activity of its investigational drug, pralatrexate, in colon, ovarian, lung, prostate, and head and neck cancer cell lines.
  - **Array BioPharma** (Boulder) presented data on the anti-tumor activity in hematological cancers of ARRY-614, a novel, small-molecule p38 / Tie2 inhibitor.
- **Baxa Corporation** announces the launch of its 'ecological' program to encourage smart use of natural resources. Joining the 'green generation,' Baxa has put in place actions to celebrate Earth Day 2009 and create meaningful environmental change. Historically, Baxa has chosen product designs and raw materials that reduce waste and improve patient safety and minimize environmental impact. More recently, the company has introduced specific initiatives for reducing its environmental impact and advancing its environmental stewardship.

## PEOPLE

- Micky O'Brien has been named Global Head of Business Development for **GEL Analytics** (Golden). GEL is an analytical laboratory with past experience measuring proteins, peptides, biosimilars and endogenous compounds using mass spectrometry platforms.
- April marks the full-time return of Nobel laureate Tom Cech to CU Boulder after his 10 year tenure as president of the Howard Hughes Medical Institute. Cech will head The Colorado

Initiative in Molecular Biotechnology along with continuing his research on RNA's interaction with proteins and teaching. Additionally, Cech will be the lunch keynote speaker at the Rocky Mountain Life Science Investor Conference on September 17th at The Ritz Carlton Denver ([www.rmlic.com](http://www.rmlic.com)).

## SQUARE PEGS

- The Presenter Selection Committee is now reviewing applications for company presentations for the 17th Annual BioPartnering Europe London (BPE) conference taking place 11 – 13 October 2009, in London, UK. In addition, we are taking reservations for our new “Spotlight on Biotechnology” exhibition hall and our one and two day dedicated meeting spaces.
- The Colorado BioScience Association's Education Committee is looking for companies that are interested in the externship program for this summer. They are interested in all companies, especially those involved in the sciences> For more information or to submit your company's name, please contact John Collar at 303-592-4072, or [jcollar@cobioscience.com](mailto:jcollar@cobioscience.com).

## UPCOMING EVENTS

- **CBSA's annual all member meeting** will take place from 4:00-6:00 pm on Tuesday, April 21 at the Colorado National Golf Club (formerly Vista Ridge) in Erie. The meeting will offer members a chance to learn more about association business including committee activities and to vote on the new officers and directors of the association. More information is available [here](#).
- Colorado State University will host the 4th annual BioTech Connect on April 21 beginning at 8 am. The event seeks to bring the BioTech community of Northern Colorado together with students and faculty at Colorado State University. More information and registration details are available [here](#).
- The next **BioBreakfast** will occur on April 29 at 7:30 at the Anschutz Medical Campus and feature “Two Colorado Companies Making a Splash” highlighting Sharklet Technologies and BioAmps. More details and registration information are available here. [here](#).
- Apply Now: **The Rocky Mountain Life Science Investor Conference** is now accepting presenting company applications. Thirty of this region's most innovative private and public life science companies will present to a targeted audience of device, diagnostic and pharma investors. Increase your companies profile with a 20 minute presentation – apply at [www.rmlic.com](http://www.rmlic.com).

## LEGISLATIVE UPDATE

- CBSA's lobbying team, have provided this week's legislative report.

Advance Colorado Center • 1625 Broadway Suite 950 • Denver Colorado 80202  
Phone: 303-592-4073 • Fax: 303-592-4081 • [www.CoBioScience.com](http://www.CoBioScience.com)